on March 31, 2009.
ITMN-191 Program in HCV:
-- Assuming submitted abstracts will be accepted, InterMune expects to
present several abstracts on ITMN-191 at AASLD, scheduled for
October 31 - November 4 in San Francisco. These abstracts pertain
to various clinical studies on ITMN-191 and in-vitro studies of
ITMN-191 in combination with other direct antiviral compounds.
-- InterMune expects to announce top-line results from the currently
running 14-day study of ITMN-191 in combination with Pegasys and
ribavirin in the fourth quarter of 2008.
Conference Call and Webcast Details
InterMune will host a conference call today at 4:30 p.m. EDT to discuss its financial results for the second quarter 2008, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 57393097. A replay of the webcast and teleconference will be available approximately three hours after the call.
To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 57393097. The webcast will remain available on the company's website until the next earnings call.
InterMune is a biotechnology company focused on the research,
development and commercialization of innovative therapies in pulmonology
and hepatology. InterMune has a pipeline portfo
|SOURCE InterMune, Inc.|
Copyright©2008 PR Newswire.
All rights reserved